

EuroSIDA Newsletter

May 2017



ANNOUNCEMENTS

Dear EuroSIDA Study Investigators,

Many greetings to all of you from the EuroSIDA coordinating office. We thank you again for your continued excellent work and important contributions to the EuroSIDA study. Below follows an update from the EuroSIDA study.

Study updates

Dataset 45

The next EuroSIDA dataset (45) has been moved to **1st October 2017**. We apologize for any inconvenience this may cause to you in your planning.

Future EuroSIDA datasets will as planned be released once a year, however we now plan to release a dataset every 1st October instead of every 1st of June. There are several reasons for this move. Firstly, we have listened to concerns from investigators about the follow-up period interfering with the summer holidays. Secondly, EuroSIDA will participate in the newly formed International Cohort Consortium of Infectious Diseases (RESPOND). Since EuroSIDA will contribute as a stakeholder in RESPOND there has been a need to align study designs. The most appropriate data collection schedule has thus been determined to be 1st October.

Please let us know at the coordinating centre if you have any questions or concerns regarding the change in data collection.

RESPOND

The design of the RESPOND consortium is under final implementation. RESPOND is a flexible generic consortium build up around modular data collection with a core data collection module onto which additional modules can be added. As mentioned, EuroSIDA contributes as a stakeholder and as one of many cohorts contributing data to RESPOND. In addition to ongoing modules on HIV and HCV co-infected patients and CoDe, EuroSIDA will provide data to two new RESPOND modules:

- INSTI Module: Integrase inhibitors: Uptake, Use of and Outcomes
- PCV Module: HIV Pharmacovigilance Research

The core data in RESPOND is build up around EuroSIDA core data. However, additional data will be requested and added to the FU-forms to support the PCV and INSTI modules. This also means that

Deadlines:

**Please continue to complete
HCV Treatment and Adverse
Event forms, INSTI HSR form, and
CoDe form when relevant.
The next dataset (45) is
released
1 October 2017**

Steering Committee elections

During 2017 EuroSIDA Steering Committee elections will be held. You will soon receive more information about the process, but you can already now start thinking about potential candidacies.

Contracts and reimbursement

The coordinating centre is in the process of developing new contracts which will be sent to all sites for review and signatures in the near future. Former EuroCoord partner sites will also be reimbursed for their EuroSIDA activities in DS42-DS43, at the next reimbursement. The next reimbursement covering DS44 activities is planned for October/November 2017. We thank all for your understanding and patience.

Plasma samples

Plasma sample should still if possible be collected twice a year for all patients participating in EuroSIDA. This can occur together with any scheduled visit to the clinic.

EuroSIDA study documents

Please remember that you can find relevant study documents [HERE](#).

Event forms will be reintroduced as known from the D:A:D study. However, in contrast to events collected in D:A:D, **source documentation will NOT** be required for RESPOND events and Event forms will be implemented in REDCap.

For you, this means that EuroSIDA data collection will continue as usual with annual data collection from 1 October. The format of data reporting will also be the same, however, with some extra data items added to the FU form.

We are very excited about RESPOND and the secured continuation of our cohort activities. RESPOND will have the flexibility and willingness to answer the most important questions of interest to the infectious diseases research community

More information will follow, but please don't hesitate to write us with any questions at the coordinating centre.



EuroSIDA scientific interest groups

The 7 **EuroSIDA Scientific Interest Groups** are progressing impressively, identifying innovative and strong research proposals. We still invite all of you to participate in the SIGs to help shape a future research agenda that will improve care and outcomes for PLHIV.

Please contact the EuroSIDA coordinating centre if you have not yet joined a SIG and you wish to participate and contribute with new research proposals. Please find the SIGs and upcoming TC's [HERE](#).

To help the SIGs move project proposals forward, documents have been developed outlining the necessary steps and considerations as well as a budget sheet to assist with building budgets for funding applications. Please find them all [HERE](#).

PUBLICATIONS

Total number of publications in 2017: 7

Publications since last newsletter February 2016: 3

Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? Peters L, Cozzi-Lepri A; Hepatitis C Working Group for the Collaboration of Observational HIV Research Europe (COHERE) in EuroCoord. AIDS. 2017;31(5):661-668.

Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.

Change in staff and REDCap login

Please remember to update the EuroSIDA coordinating centre if there are changes to staff. This allows information, newsletters etc. to be sent to the right person and also allows us to keep the study group updated and thus award co-authorships to the right people. Furthermore, if staff no longer works at your site, we need to remove their REDCap access.

Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosidea.rigshospitalet@regionh.dk. No question is too small or too big, we are happy to assist in all matters!



Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

HIV Med. 2017;18(3):171-180.

IN PRESS

Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholz L, Kyselyova G, Lungren JD, Mocroft A; for EuroSIDA. Clin Infect Dis. 2017 Feb 22. [Epub ahead of print].

Predictors of eGFR Progression, Stabilisation or Improvement After Chronic Renal Impairment in HIV-positive individuals. L Ryom, A Mocroft, O Kirk, M Ross, C Smith, O Moranne, P Morlat, CA FUX; C Sabin, A Phillips, M Law, JD Lundgren. On behalf of the D:A:D Study group. AIDS. 2017 Mar 28. [Epub ahead of print].

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Chêne G, Phillips A, Costagliola D, Sterne JA, Furrer H, Del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbøl Brandt R, Friis-Møller N, Raben D, Haerry D, Egger M, Weller I, De Wit S. Int J Epidemiol. 2016 Nov 17. [Epub ahead of print].

All EuroSIDA publications may be found [HERE](#)

Thank you for a continuous rewarding collaboration and for your invaluable contributions to EuroSIDA!